Modality
ASO
MOA
BCMA ADC
Target
FLT3
Pathway
Angiogenesis
CRC
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Aug 2031
Phase 3Current
NCT05980156
642 pts·CRC
2017-04→2031-08·Terminated
642 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-145.4y awayPh3 Readout· CRC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2031-08-14 · 5.4y away
CRC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05980156 | Phase 3 | CRC | Terminated | 642 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 |